

CLAIM AMENDMENTS

1.-4. (cancelled)

5. (currently amended) A recombinant antibody recognizing IOR C2 antigen, the recombinant antibody being produced from murine monoclonal antibody IOR C5 produced by the hybridoma deposited with the European Collection of Cell Cultures under accession number 97061101, wherein said recombinant antibody comprises Complementary Determining Regions (CDRs) and framework regions (FRs) of the murine monoclonal antibody IOR C5 and humanized constant regions in its light and heavy chains, and wherein the heavy and light chains comprise at least one framework region point mutation ~~The recombinant antibody according to claim 1, wherein the framework region point mutation is selected from the group consisting of:~~

HEAVY CHAIN:

Position 10 ASP for GLY

Position 17 SER for THR

Position 43 ASN for LYS

Position 44 LYS for GLY

LIGHT CHAIN:

Position 15 ILE for LEU

Position 45 LYS for ARG

Position 63 THR for SER

6. (cancelled)

7. (currently amended) Cellular line expressing the recombinant antibody of claim
~~claims 1 or 5.~~

8. (currently amended) Host cell which expresses ~~express~~ the single chain Fv
fragment of claim ~~claims 16 or 17.~~

9. (currently amended) Pharmaceutical composition for treating recto and colon
~~malignant tumors, metastasis thereof and recurrences, comprising the recombinant~~
antibody of claim ~~claims 1 or 5~~ and a suitable excipient.

10. (currently amended) Pharmaceutical composition for treating recto and colon
malignant tumors, metastasis thereof and recurrences, comprising the single chain Fv
fragment of claim ~~claims 16 or 17~~ and a suitable excipient.

11. (currently amended) Pharmaceutical composition for localization and identification
“*in vivo*” of recto and colon malignant tumors, metastasis thereof and recurrences,
comprising the recombinant antibody of claim ~~claims 1 or 5.~~

12. (currently amended) Pharmaceutical composition for localization and identification "*in vivo*" of recto and colon malignant tumors, metastasis thereof and recurrences, comprising the single chain Fv fragment of claim ~~claims 16 or 17~~.

13. (previously presented) Pharmaceutical composition according to claims 9 or 11 comprising also compounds for radiolabeling the antibodies.

14. (previously presented) Pharmaceutical composition according to claim 13 comprising technetium 99, rhenium 186, rhenium 188 or analogues as radiolabelers.

15. (cancelled)

16. (cancelled)

17. (currently amended) A single chain Fv fragment recognizing IOR C2 antigen, the Fv fragment being produced from murine monoclonal antibody IOR C5 produced by the hybridoma deposited with the European Collection of Cell Cultures under accession number 97061101, said Fv fragment containing the Complementary Determining Regions (CDRs) and frameworks regions (FRs) of the murine monoclonal antibody IOR C5 and humanized constant regions in its heavy and light chains, wherein the heavy and light chains comprise at least one framework region point mutation ~~The single chain Fv fragment according to claim 16, wherein the framework region point mutation is~~ selected from the group consisting of:

HEAVY CHAIN:

Position 10 ASP by GLY

Position 17 SER by THR

Position 43 ASN by LYS

Position 44 LYS by GLY

LIGHT CHAIN:

Position 15 ILE by LEU

Position 45 LYS by ARG

Position 63 THR by SER

18. (previously presented) Pharmaceutical composition according to claims 10 or 12 further comprising compounds for radiolabeling the Fv fragments.

19. (previously presented) Pharmaceutical composition according to claim 18 comprising technetium 99, rhenium 186, rhenium 188 or analogues as radiolabelers.